Skip to Main content Skip to Navigation
Journal articles

Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma

Abstract : Brain tumors actively reprogram their cellular metabolism to survive and proliferate, thus offering potential therapeutic opportunities. Over the past decade, extensive research has been done on mutant IDH enzymes as markers of good prognosis in glioblastoma, a highly aggressive brain tumor in adults with dismal prognosis. Yet, 95% of glioblastoma are IDH wild-type. Here, we review current knowledge about IDH wild-type enzymes and their putative role in mechanisms driving tumor progression. After a brief overview on tumor metabolic adaptation, we present the diverse metabolic function of IDH enzymes and their roles in glioblastoma initiation, progression and response to treatments. Finally, we will discuss wild-type IDH targeting in primary glioblastoma.
Document type :
Journal articles
Complete list of metadata
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Thursday, November 18, 2021 - 11:07:22 AM
Last modification on : Wednesday, April 27, 2022 - 4:22:24 AM
Long-term archiving on: : Saturday, February 19, 2022 - 6:42:07 PM


Publication funded by an institution



Gabriel Alzial, Ophelie Renoult, François Paris, Catherine Gratas, Anne Clavreul, et al.. Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma. Oncogene, Nature Publishing Group, 2021, Online ahead of print. ⟨10.1038/s41388-021-02056-1⟩. ⟨inserm-03434277⟩



Record views


Files downloads